Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MicroMed predicts Q4 start for DELTA ONE trial:

This article was originally published in Clinica

Executive Summary

MicroMed Technology has submitted an investigational device exemption (IDE) application to the US FDA to start a clinical trial to assess its miniaturised cardiac assist device as a long-term treatment for heart failure patients who are not eligible for heart transplantation. The DeBakey ventricular assist device is currently being tested in a pivotal trial in the US as a bridge to transplant and is already approved for sale in Europe. The Houston, Texas firm said that pending FDA approval of the IDE, it planned to begin the new trial, called DELTA ONE, by the fourth quarter of 2002.

You may also be interested in...



ASTM Developing Standard To Tackle Dried Blood On Steel Devices

ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.

Executives On The Move: CEOs Named At Elevation Oncology, PainReform Ltd

Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma

Viatris Kickstarts Business With Tentative Approval For Pediatric Dolutegravir

The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program. 

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel